Asymmetry Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Asymmetry Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-155,232	Closed	-$8.56M	–	44
2020 Q3	$8.56M	Sell	155,232 -16,084	-9%	-$1.02M	5.5%	4
2020 Q2	$10.8M	Buy	171,316 +84,739	+98%	+$5.81M	8.29%	3
2020 Q1	$4.42M	Buy	+86,577	New	+$5.8M	4.84%	8
2019 Q4	–	Sell	-75,011	Closed	-$3.64M	–	41
2019 Q3	$3.64M	Sell	75,011 -239,206	-76%	-$12.5M	7.8%	4
2019 Q2	$16.5M	Buy	314,217 +228,556	+267%	+$13.1M	8.95%	2
2019 Q1	$4.53M	Sell	85,661 -21,023	-20%	-$1.03M	7.58%	5
2018 Q4	$4.38M	Buy	106,684 +3,235	+3%	+$121K	12.1%	2
2018 Q3	$3.93M	Buy	103,449 +54,094	+110%	+$2.4M	3.63%	9
2018 Q2	$2.23M	Buy	49,355 +27,355	+124%	+$1.25M	2.19%	18
2018 Q1	$1.06M	Buy	+22,000	New	+$1.23M	1.33%	27

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Asymmetry Capital Management's GBT Position: Q4 2020 in Review

Asymmetry Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 155,232 shares — an estimated $8.56M sold.

Asymmetry Capital Management first reported a position in GBT in Q1 2018 and held it in 10 quarters. The position peaked at $16.5M in Q2 2019. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

Asymmetry Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
Asymmetry Capital Management sold 155,232 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $8.56M.
Asymmetry Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 10 quarters.
Asymmetry Capital Management's Global Blood Therapeutics, Inc. position peaked at $16.5M in Q2 2019.
228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Asymmetry Capital Management's 13F filing for Q4 2020, filed 11 Feb 2021.